The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
From the RNS:
"The license agreement includes an upfront payment to the Company, along with a number of further payments conditional upon operational deliverables related to technology transfer and related publications."
Unknown as to how much 'upfront'.
Previous guidance was they were fully funded until mid 2024. (but who knows)
They are hitting very positive milestones increasing the commerciality of the company and thus the value of the company.
They will either be a successful profitable company or they will be taken over by a bigger fish!
Either at a substantial premium to todays mcap imho.
GL.
Unexpectedly very good news!
Mcap < than 1m worth a punt?
"I am delighted with the support shown by our lender, the Spartan Fund Limited SAC. Echo is full steam ahead originating and negotiating multiple business development opportunities and we look forward to updating investors in due course."
GL.
'The strong results were particularly noteworthy given that the study utilised a generalised 'all-comers' patient population rather than a specific subgroup and examined performance in both the for-cause and surveillance settings. The study was purposefully designed this way to capture the clinical reality across 13 international transplant centres in five countries. As a result, the data reflects the wide clinical applicability of Tutivia? for comprehensive commercial adoption in a real-world setting.'
GL.